 |
 |
 |
|
 |
Friday, May 22, 2015 |
Read More
 |
Ethical Violations in Zimbabwe’s Clinical Trial |
| The monitoring and supervision of clinical trials in Zimbabwe have showed ethical violations related to protecting the rights of clinical trial participants.
According to a report serious issues were observed in the current system of clinical trials oversight which was demonstrated by the story of an HIV-positive Zimbabwean woman attacked by blindness during her trial participation. The trial was related with the second-line treatment for HIV...... Read More |
|
| Bioethics Panel Created by Johnson and Johnson on trial drugs |  |
| A nationally known bioethicist had been appointed by Johnson and Johnson to create a panel that will make decisions about patients’ requests for potentially lifesaving medicine. This was done corresponding to debate over whether companies should allow severely ill people to have access to the drugs before they are approved.
This type of initiative has been taken for the first time and it is believed that other drug companies will be also inspired by this on account of Johnson and Johnson being a major giant pharmaceutical industry. Growing number of patients with terminal.... Read More |
|
 |
New manufacturing clinical trial models by India to sell generics to Japan |
| For several years, Japan’s policy has been to emphasize prescriptions for generic rather than branded versions of drugs to lower its national health-insurance costs.
The head of India’s Pharmaceuticals Export Promotion Council of India (Pharmexcil) said that about 20 Japan-based companies have shown an interest in contract manufacturing in India. Pharmexcil is expected to hold discussions with the Japan companies in July. Read More |
|
| Two biosimilar drugs from BIOCON enter global phase 3 clinical trials |  |
| Biocon is an Asia's premier biotechnology company and has one of the largest generic insulin analogs and biosimilars in advanced stages of development. BIOCON has made clinical progress in its partnered programs with Mylan. The partnership has a strong focus on generic insulin analogs and biosimilars including Monoclonal Antibodies (MAbs) and recombinant proteins at various stages of development.
The partnership represents significant progress....... Read More |
|